Metsera Inc (MTSR)

$51.90 +0.20 (0.39%)
Market Cap 5.45B
Revenue (ttm) 0.00
Net Income (ttm) -209.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,059,000
Avg Vol 2,339,470
Day's Range N/A - N/A
Shares Out 105.06M
Stochastic %K 27%
Beta N/A
Analysts Strong Sell
Price Target $55.75

Company Profile

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, N...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 784 6595
Website: metsera.com
Address:
3 World Trade Center, 175 Greenwich Street, New York, United States
Schematic045
Schematic045 Oct. 3 at 9:53 PM
$PFE $MPC $MPLX $MTSR 2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October You don Pfizer stock yields over 6%. MPLX LP, a pipeline operator, currently yields above 7%. Both companies are positioned to sustain dividend growth for years ahead.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 3 at 3:13 PM
$MTSR Current Stock Price: $51.82 Contracts to trade: $50 MTSR Oct 17 2025 Call Entry: $1.90 Exit: $3.15 ROI: 66% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 3:51 AM
$MTSR: Unusual Options Activity Alerted PUT flow observed 50x contracts at Strike price of $55 Exp on 02/20/2026 with Premium of $42K and showing BEARISH Sentiment
0 · Reply
clgkaan9926u
clgkaan9926u Oct. 3 at 1:13 AM
$PFE $MTSR 3 Things You Need to Know if You Buy Pfizer Today Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it. Pfizer is a major drugmaker with a history of navigating difficult periods. The company faces challenges from an impending patent cliff. Its dividend payout ratio is high, which could put the dividend at risk.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 3:24 PM
$MTSR: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $45 Exp on 10/17/2025 with Premium of $73K and showing BULLISH Sentiment
0 · Reply
FE123
FE123 Oct. 1 at 9:47 PM
$VKTX Come on $MTSR over $52, $VKTX Should be also over $50!
0 · Reply
inflect1on
inflect1on Oct. 1 at 4:01 PM
$PFE new “rx” model utilizing their platform to combat $GDRX moat while also actually in the competition now against $LLY with glp1 medications following $MTSR acquisition?
1 · Reply
BioRich
BioRich Oct. 1 at 1:22 PM
$ALT Morning Reality Check (The Dreaded Chart): If you have invested in $GUTS a month ago, you'd have a better return than 2 companies that got bought out ($MTSR and $ETNB) and a 60+% gain over $ALT. When I suggest that $ALT is dead and folks are better suited taking the tax loss and investing in $GUTS, I wasn't kidding. You would have made all of your money back, rather than pumping the next hopeful event. Reality is not your friend $ALT'ers. Listen, learn and act. Holding on to your bags for emotional and group therapy reasons isn't going to make you Rich. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI
0 · Reply
skpbnnd6953l
skpbnnd6953l Sep. 30 at 6:51 PM
$PFE $MTSR Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market. Pfizer is acquiring a pharma company with multiple GLP-1 drugs in development. The deal may cost up to $7.3 billion, a move Pfizer can afford given its strong financials.
0 · Reply
DARKP00L
DARKP00L Sep. 30 at 5:02 PM
$MTSR 12:58 on Sep. 30 2025 Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial #tradeideas
0 · Reply
Latest News on MTSR
Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug

Sep 30, 2025, 3:39 PM EDT - 4 days ago

Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug

PFE

Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.

Sep 30, 2025, 11:02 AM EDT - 4 days ago

Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.

PFE

Metsera's obesity drug shows promising weight loss in mid-stage trials

Sep 29, 2025, 4:11 PM EDT - 5 days ago

Metsera's obesity drug shows promising weight loss in mid-stage trials

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

Sep 29, 2025, 4:01 PM EDT - 5 days ago

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

Sep 23, 2025, 6:00 PM EDT - 11 days ago

METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

PFE

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

Sep 22, 2025, 2:50 PM EDT - 12 days ago

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

PFE

BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity

Sep 22, 2025, 2:01 PM EDT - 12 days ago

BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity

PFE

Wedbush Ups AAPL Price Target, PFE Acquires MTSR, Morgan Stanley Chip Upgrades

Sep 22, 2025, 10:01 AM EDT - 12 days ago

Wedbush Ups AAPL Price Target, PFE Acquires MTSR, Morgan Stanley Chip Upgrades

AAPL PFE MS

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal

Sep 22, 2025, 9:16 AM EDT - 12 days ago

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal

PFE

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Sep 22, 2025, 9:09 AM EDT - 12 days ago

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

PFE

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera

Sep 22, 2025, 8:59 AM EDT - 12 days ago

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera

PFE

Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal

Sep 22, 2025, 8:14 AM EDT - 12 days ago

Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal

PFE

Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight

Sep 22, 2025, 8:05 AM EDT - 12 days ago

Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight

INTC PFE

This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer

Sep 22, 2025, 7:42 AM EDT - 12 days ago

This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer

PFE

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

Sep 22, 2025, 7:02 AM EDT - 12 days ago

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

PFE

Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion

Sep 22, 2025, 6:54 AM EDT - 12 days ago

Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion

PFE

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

Sep 22, 2025, 6:45 AM EDT - 12 days ago

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

PFE

Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug

Sep 22, 2025, 1:55 AM EDT - 13 days ago

Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug

PFE

Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports

Sep 22, 2025, 12:04 AM EDT - 13 days ago

Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports

PFE

Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting

Sep 11, 2025, 7:00 AM EDT - 23 days ago

Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting

Metsera to Present at Upcoming September Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 5 weeks ago

Metsera to Present at Upcoming September Investor Conferences

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

Jul 28, 2025, 4:01 PM EDT - 2 months ago

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 7:00 AM EDT - 4 months ago

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Jun 9, 2025, 2:07 PM EDT - 4 months ago

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Jun 9, 2025, 12:04 PM EDT - 4 months ago

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Jun 9, 2025, 7:00 AM EDT - 4 months ago

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Jun 5, 2025, 7:30 AM EDT - 4 months ago

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

May 12, 2025, 7:00 AM EDT - 5 months ago

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

Metsera to Present at Bank of America 2025 Global Healthcare Conference

May 8, 2025, 4:01 PM EDT - 5 months ago

Metsera to Present at Bank of America 2025 Global Healthcare Conference

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Mar 26, 2025, 7:00 AM EDT - 6 months ago

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

Feb 26, 2025, 7:00 AM EST - 7 months ago

Metsera to Present at TD Cowen's 45th Annual Health Care Conference

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Feb 26, 2025, 3:55 AM EST - 7 months ago

Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation

Why this newly public biotech could become a force in obesity treatments

Feb 25, 2025, 1:42 PM EST - 7 months ago

Why this newly public biotech could become a force in obesity treatments

This weight-loss drug stock could deliver a 90% return in 2025

Feb 25, 2025, 8:47 AM EST - 7 months ago

This weight-loss drug stock could deliver a 90% return in 2025

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

Feb 5, 2025, 4:01 PM EST - 8 months ago

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Feb 1, 2025, 2:10 AM EST - 8 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MAZE ODTX ODYS SAIL

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Jan 31, 2025, 12:42 PM EST - 8 months ago

Weight-loss drug developer Metsera valued at $2.68 bln as shares jumped in market debut

Weight-loss drug developer Metsera raises $275 million in US IPO

Jan 30, 2025, 7:05 PM EST - 8 months ago

Weight-loss drug developer Metsera raises $275 million in US IPO

Metsera Announces Pricing of Initial Public Offering

Jan 30, 2025, 6:53 PM EST - 8 months ago

Metsera Announces Pricing of Initial Public Offering

Metsera Readies $275 Million IPO For Obesity Treatments

Jan 28, 2025, 4:48 PM EST - 8 months ago

Metsera Readies $275 Million IPO For Obesity Treatments

Schematic045
Schematic045 Oct. 3 at 9:53 PM
$PFE $MPC $MPLX $MTSR 2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October You don Pfizer stock yields over 6%. MPLX LP, a pipeline operator, currently yields above 7%. Both companies are positioned to sustain dividend growth for years ahead.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 3 at 3:13 PM
$MTSR Current Stock Price: $51.82 Contracts to trade: $50 MTSR Oct 17 2025 Call Entry: $1.90 Exit: $3.15 ROI: 66% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 3:51 AM
$MTSR: Unusual Options Activity Alerted PUT flow observed 50x contracts at Strike price of $55 Exp on 02/20/2026 with Premium of $42K and showing BEARISH Sentiment
0 · Reply
clgkaan9926u
clgkaan9926u Oct. 3 at 1:13 AM
$PFE $MTSR 3 Things You Need to Know if You Buy Pfizer Today Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it. Pfizer is a major drugmaker with a history of navigating difficult periods. The company faces challenges from an impending patent cliff. Its dividend payout ratio is high, which could put the dividend at risk.
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 3:24 PM
$MTSR: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $45 Exp on 10/17/2025 with Premium of $73K and showing BULLISH Sentiment
0 · Reply
FE123
FE123 Oct. 1 at 9:47 PM
$VKTX Come on $MTSR over $52, $VKTX Should be also over $50!
0 · Reply
inflect1on
inflect1on Oct. 1 at 4:01 PM
$PFE new “rx” model utilizing their platform to combat $GDRX moat while also actually in the competition now against $LLY with glp1 medications following $MTSR acquisition?
1 · Reply
BioRich
BioRich Oct. 1 at 1:22 PM
$ALT Morning Reality Check (The Dreaded Chart): If you have invested in $GUTS a month ago, you'd have a better return than 2 companies that got bought out ($MTSR and $ETNB) and a 60+% gain over $ALT. When I suggest that $ALT is dead and folks are better suited taking the tax loss and investing in $GUTS, I wasn't kidding. You would have made all of your money back, rather than pumping the next hopeful event. Reality is not your friend $ALT'ers. Listen, learn and act. Holding on to your bags for emotional and group therapy reasons isn't going to make you Rich. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI
0 · Reply
skpbnnd6953l
skpbnnd6953l Sep. 30 at 6:51 PM
$PFE $MTSR Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market. Pfizer is acquiring a pharma company with multiple GLP-1 drugs in development. The deal may cost up to $7.3 billion, a move Pfizer can afford given its strong financials.
0 · Reply
DARKP00L
DARKP00L Sep. 30 at 5:02 PM
$MTSR 12:58 on Sep. 30 2025 Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial #tradeideas
0 · Reply
inspector_gadget86
inspector_gadget86 Sep. 30 at 4:07 PM
$MTSR $PFE Trump, Pfizer announce agreement to lower Medicaid drug prices $TRUMP.X $DJT
0 · Reply
himsssss
himsssss Sep. 30 at 3:34 PM
$MTSR $VKTX The data is excellent and validated PFEs decision to buy metsera. Only people who are arguing otherwise always had malice for Metsera, check their post history. Comparisons are being drawn to existing obesity / weight-loss therapies: with 14.1% weight loss, MET-097i is viewed as competitive with, or possibly even surpassing, some current GLP-1 / multi-agonist standards like tirzepatide. I'm holding every single share from an average of $21.XX. Why? The management here just set a floor price for us with the PFE deal, locking in $70/share. CVR alone covers my cost basis but here is the real kicker. Metsera can break this deal off anytime, Pfizer can't. This means that other BP can sweep in to price out PFE and start a bidding war.
2 · Reply
morelong_lessshort
morelong_lessshort Sep. 30 at 3:29 PM
$IOVA $MTSR $PFE $VKTX As much as I believe BL is effective in the lab with the studies, he will not provide a catalyst until the lab results are prepared and ready. He’s a good CEO candidate for shorts as he conveys the schedule clearly which then is a roadmap mitigating the shorts risk.
1 · Reply
PensionPulse
PensionPulse Sep. 30 at 3:19 PM
$VKTX So $PFE buys out $MTSR and people automatically assume that's it, that's all she wrote for Viking. This stock was breaking out nicely over $40 and then the hedge fund mafia took it down after p2 results to scoop up shares on the cheap. Now it's coiling hard, we need a catalyst to break out of this tight range. Very frustrating stock, almost as bad as $IOVA.
2 · Reply
BiotechAndAI94
BiotechAndAI94 Sep. 30 at 2:36 PM
$MTSR $PFE speaking of market mechanics, the pfizer deal will help their Metsera pipeline get more access. An L for the haters at other stocks.
0 · Reply
judgeyoung2
judgeyoung2 Sep. 30 at 2:22 PM
$PFE this is up after positive $MTSR data? but all the Viking pumpers told me that Pfizer made an awful choice buying Metsera 🙊
1 · Reply
GPTInsights
GPTInsights Sep. 30 at 1:47 PM
$VKTX down on subpar $MTSR data with no details on side effects? Shady and feels like the market is intentionally misrepresenting data as negative for Viking despite the actual numbers. We should be green today --- this is just another competitor that greatly failed to outperform VK2735.
0 · Reply
Polip
Polip Sep. 30 at 9:06 AM
$PFE Bourla bought the wrong horse $MTSR
1 · Reply
highnihilism
highnihilism Sep. 30 at 8:40 AM
$LIF Life360: 52 trades, $150K vs $108K avg (1.39x). $136K calls / $14K puts. $MTSR Metsera: 170 trades, $295K vs $253K avg (1.17x). $136K calls / $159K puts. $DVS Dolly Varden Silver: 101 trades, $138K vs $15.5K avg (8.89x !!). $136K calls / $2K puts. $CRNC Cerence: 444 trades, $190K vs $346K avg (0.55x). $135K calls / $55K puts.
0 · Reply
raticals
raticals Sep. 30 at 2:59 AM
$VKTX $MTSR so let me get this straight. Viking reports oral data that freaked everyone one out about AE percentages. They report percentages from the start of their trial. Metsera on the other hand just released their injectible data and decided to report AEs starting at week 12. If Viking did the same the AE data would have been off the charts awesome. How can companies like Metsera cherry pick what to PR?
5 · Reply
raticals
raticals Sep. 30 at 1:22 AM
$VKTX $MTSR super curious how Metsera has their placebo arms having weight gains thru their trials, while everyone else’s placebo lost some weight. With that being said why are they even compared against the placebo for weight loss metrics. I get tolerability but placebo adjusted metrics are dumb.
2 · Reply
GPTInsights
GPTInsights Sep. 30 at 1:09 AM
$VKTX sooo $MTSR decent results but took them twice as long to achieve what viking did?
1 · Reply